Table 3. Agents in phase III clinical trials for AD treatments.
Name |
Company |
Mechanism of action or target |
Reference |
AC-1202 |
Accera |
Not disclosed |
168 |
AC-1204 |
Accera |
Stimulation of metabolic processes |
174 |
Aducanumab |
Biogen Co. |
Anti beta-amyloid |
39 |
ALZT-OP1 |
AZ Therapeutics |
Prevents aggregation of beta-amyloid |
69 |
AVP-786 (CTP-786) |
Avanir Pharmaceuticals |
NMDAR antagonist |
103 |
AZD-3293 (LY-3314814) |
AstraZeneca, Eli Lilly |
Inhibitors of beta-secretase (BACE-1) |
63 |
Bapineuzumab |
OOP&Johnson |
Humanized monoclonal antibody acting on soluble forms of amyloid |
44, 45 |
Crenezumab |
AC Immune and Genetech |
Anti beta-amyloid |
54 |
Encenicline hydrochloride |
Bayer |
Acetylcholine (nicotinic) receptors ligand, nicotinic alpha-7-nAChR agonist |
98 |
Epigallocatechin Gallate |
Taiyo International |
Amyloid-related, antioxidant |
164 |
Gammagard |
Baxalta |
Anti beta-amyloid |
42, 43 |
Gantenerumab |
Hoffmann-La Roche |
Anti beta-amyloid |
40 |
GV-971 |
Shanghai Green Valley |
Inhibitor beta-amyloid aggregation and neuroinflammation |
70 |
Humulin RU-100 |
NIH |
Amyloid-Related |
188, 189 |
HX-106 |
VitroMed |
Antioxidant |
163 |
Insulin detemir (Levemir/Levemir300) |
Novo Nordisk |
Not disclosed |
190 |
Intepirdine (SB-742457) |
GlaxoSmithKline |
5-HT6 receptor antagonist |
93 |
JNJ-54861911 |
Janssen |
BACE inhibitor |
64 |
Lu-AE-58054 |
Lundbeck |
Serotonin receptors (5-Hydrotryptamine) |
92 |
Masitinib mesylate |
AB Science |
Inhibitor of c-KIT receptor, growth factor receptor (PDGFR), fibroblast growth factor receptor-3 (FGFR-3) tyrosine kinases |
109 |
Memryte |
Durect, Curaxis Pharmaceutical |
Durin-leuprolide acetate and GnRH (LHRH) receptor agonist |
108 |
MK8931 (Verubecestat) |
Merck&Co |
BACE-1 inhibitor |
62 |
Nilvadipine (ARC-029) |
Astellas Pharma |
Calcium channel blocker, antioxidant |
110 |
Pioglitazone |
Takeda |
Inflammation |
194 |
Resveratrol |
Solgar, Country Life, MRM |
Multitarget: antioxidant, MAO-A, beta-secretase, xanthine oxidase, NF-kappaB |
169, 170 |
Scyllo-Inositol (ELND005) |
Transition Therapeutics |
Inhibitor of amyloid beta peptide aggregation |
72 |
SK-PC-B70M |
SK Chemicals |
Antioxidant |
165 |
Solanezumab |
Ely Lilly |
Anti beta-amyloid |
37, 38 |
Tramiprosate |
Neurochem |
Anti-amyloid |
76 |
TRx-00237 |
Janssen, Pfizer, TauRx Therapeutics |
Amyloid-Related, Tau aggregation |
88 |